Skip to main content
Top

Breast Cancer Research

Issue 2/2010

Content (18 Articles)

Erratum

Erratum to: PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

Gordon C Wishart, Elizabeth M Azzato, David C Greenberg, Jem Rashbass, Olive Kearins, Gill Lawrence, Carlos Caldas, Paul DP Pharoah

Open Access Research article

Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study

Deirdre P Cronin-Fenton, Lars Pedersen, Timothy L Lash, Søren Friis, John A Baron, Henrik T Sørensen

Editorial

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?

Sunil R Lakhani, Kum Kum Khanna, Georgia Chenevix-Trench

Open Access Research article

Effects of lovastatin on breast cancer cells: a proteo-metabonomic study

Jelena Klawitter, Touraj Shokati, Vanessa Moll, Uwe Christians, Jost Klawitter

Open Access Research article

Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins

Hideki Asakawa, Hirotaka Koizumi, Ayaka Koike, Makiko Takahashi, Wenwen Wu, Hirotaka Iwase, Mamoru Fukuda, Tomohiko Ohta

Open Access Research article

The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer

Zhi Hu, Ge Huang, Anguraj Sadanandam, Shenda Gu, Marc E Lenburg, Melody Pai, Nora Bayani, Eleanor A Blakely, Joe W Gray, Jian-Hua Mao

Open Access Research article

Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer

Jingmei Li, Louise Eriksson, Keith Humphreys, Kamila Czene, Jianjun Liu, Rulla M Tamimi, Sara Lindström, David J Hunter, Celine M Vachon, Fergus J Couch, Christopher G Scott, Pagona Lagiou, Per Hall

Open Access Research article

Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers

Chang Hoon Song, So Yeon Park, Keun-Yong Eom, Jee Hyun Kim, Sung-Won Kim, Jae Sung Kim, In Ah Kim

Open Access Research article

Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways

Elgene Lim, Di Wu, Bhupinder Pal, Toula Bouras, Marie-Liesse Asselin-Labat, François Vaillant, Hideo Yagita, Geoffrey J Lindeman, Gordon K Smyth, Jane E Visvader

Open Access Research article

Trichostatin A enhances acetylation as well as protein stability of ERα through induction of p300 protein

Sung-Hye Kim, Hyun-Jin Kang, Hyelin Na, Mi-Ock Lee

Open Access Research article

Effects of childhood body size on breast cancer tumour characteristics

Jingmei Li, Keith Humphreys, Louise Eriksson, Kamila Czene, Jianjun Liu, Per Hall

Open Access Research article

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

Christos Markopoulos, Evagelos Tzoracoleftherakis, Athanassios Polychronis, Basileios Venizelos, Urania Dafni, Grigorios Xepapadakis, John Papadiamantis, Vasilios Zobolas, John Misitzis, Kyriakos Kalogerakos, Angeliki Sarantopoulou, Nikolaos Siasos, Dimitrios Koukouras, Zoh Antonopoulou, Spyros Lazarou, Helen Gogas

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine